Adjuvant Therapy for Urothelial and Renal Cell Carcinoma

Hiten D. Patel; Max Kates; Mohamad E. Allaf

doi:10.1016/j.euf.2019.04.007

Adjuvant Therapy for Urothelial and Renal Cell Carcinoma

Hiten D. Patel, Max Kates, Mohamad E. Allaf

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

Adjuvant therapy for urothelial and renal cell carcinoma has progressed steadily over the past 30 yr. Level 1 evidence supports a role for both neoadjuvant and adjuvant cisplatin-based chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Recent evidence has also confirmed a benefit from adjuvant therapy in high-grade upper tract urothelial carcinoma. Adjuvant targeted therapy remains controversial and outside the standard of care for renal cell carcinoma, with no proven overall survival benefit. Immune checkpoint blockade is poised to shift the landscape for both urothelial and renal cell carcinoma with the potential for greater efficacy.

Original language	English (US)
Pages (from-to)	3-6
Number of pages	4
Journal	European Urology Focus
Volume	6
Issue number	1
DOIs	https://doi.org/10.1016/j.euf.2019.04.007
State	Published - Jan 15 2020

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.euf.2019.04.007

Cite this

@article{342690c93c3740e0a98a433a97e298f2,

title = "Adjuvant Therapy for Urothelial and Renal Cell Carcinoma",

abstract = "Adjuvant therapy for urothelial and renal cell carcinoma has progressed steadily over the past 30 yr. Level 1 evidence supports a role for both neoadjuvant and adjuvant cisplatin-based chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Recent evidence has also confirmed a benefit from adjuvant therapy in high-grade upper tract urothelial carcinoma. Adjuvant targeted therapy remains controversial and outside the standard of care for renal cell carcinoma, with no proven overall survival benefit. Immune checkpoint blockade is poised to shift the landscape for both urothelial and renal cell carcinoma with the potential for greater efficacy.",

author = "Patel, {Hiten D.} and Max Kates and Allaf, {Mohamad E.}",

note = "Publisher Copyright: {\textcopyright} 2019 European Association of Urology",

year = "2020",

month = jan,

day = "15",

doi = "10.1016/j.euf.2019.04.007",

language = "English (US)",

volume = "6",

pages = "3--6",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Adjuvant Therapy for Urothelial and Renal Cell Carcinoma

AU - Patel, Hiten D.

AU - Kates, Max

AU - Allaf, Mohamad E.

PY - 2020/1/15

Y1 - 2020/1/15

N2 - Adjuvant therapy for urothelial and renal cell carcinoma has progressed steadily over the past 30 yr. Level 1 evidence supports a role for both neoadjuvant and adjuvant cisplatin-based chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Recent evidence has also confirmed a benefit from adjuvant therapy in high-grade upper tract urothelial carcinoma. Adjuvant targeted therapy remains controversial and outside the standard of care for renal cell carcinoma, with no proven overall survival benefit. Immune checkpoint blockade is poised to shift the landscape for both urothelial and renal cell carcinoma with the potential for greater efficacy.

AB - Adjuvant therapy for urothelial and renal cell carcinoma has progressed steadily over the past 30 yr. Level 1 evidence supports a role for both neoadjuvant and adjuvant cisplatin-based chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Recent evidence has also confirmed a benefit from adjuvant therapy in high-grade upper tract urothelial carcinoma. Adjuvant targeted therapy remains controversial and outside the standard of care for renal cell carcinoma, with no proven overall survival benefit. Immune checkpoint blockade is poised to shift the landscape for both urothelial and renal cell carcinoma with the potential for greater efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85064689944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064689944&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.04.007

DO - 10.1016/j.euf.2019.04.007

M3 - Comment/debate

C2 - 31031041

AN - SCOPUS:85064689944

SN - 2405-4569

VL - 6

SP - 3

EP - 6

JO - European Urology Focus

JF - European Urology Focus

IS - 1

ER -

Adjuvant Therapy for Urothelial and Renal Cell Carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this